BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee12.5.2026 15:00:00 CEST | Press release
GTDC appointed V.S. Hariharan, Managing Director and Group CEO of the Redington Group, to its Executive Committee (EC) to guide strategy and provide operational oversight. The EC advances the organization's mission to educate, advocate, and influence the tech industry on the evolving role of IT distribution worldwide. Mr. Hariharan leads Redington's $11.8 billion distribution and supply chain business across 40 markets. Redington continues to strengthen its role as a Technology Orchestrator, enabling seamless connections across the ecosystem to Unlock Next opportunities for partners. TAMPA, FL / ACCESS Newswire / May 12, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distributio
Braiin Advances Proposed Acquisition of Home.cc with Valuation and Growth-Capital Components Totaling Approximately A$73 Million to Build AI-Native LivTech Platform for Residential Lifecycle Services, Targeting the $3+ Trillion Global Residential Lifecycle Services Market12.5.2026 14:15:00 CEST | Press release
Proposed acquisition would combine Home's embedded residential distribution, payments infrastructure and household-services platform with Braiin's AI, CXaaS and PropTech ecosystem MELBOURNE, AU AND LONDON, UK / ACCESS Newswire / May 12, 2026 / Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, today announced that it has entered into a non-binding term sheet to advance its proposed acquisition of Home.cc ("Home"), a Living Technology ("LivTech") platform focused on embedded residential distribution, household service activation, payments and connected living infrastructure. Under the proposed structure, Braiin would acquire a 50.1% majority interest in Cumbria Capital Ltd, the parent company of Home.cc, through a share purchase to be satisfied by the issuance of Braiin equity securities. The non-binding term sheet contemplates a p
Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB12.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA"). The SO1 Agreement is intended to be executed between PREPA and Polaris Power US, Inc ("PPUS"), a wholly owned subsidiary of Polaris. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed at strengthening grid reliability across the island through the deployment of utility-scale BESS co-located with existing generation facilities. Under this
Elixir Technologies Unveils Elixir Muse: The AI Writing Assistant Built for Total Data Privacy12.5.2026 13:00:00 CEST | Press release
Elixir's new writing assistant product delivers AI-powered drafting, revision, translation, validation, tone of voice and sentiment analysis, and compliance analysis - without storing, harvesting or training on user data. OJAI, CA / ACCESS Newswire / May 12, 2026 / Elixir Technologies today introduced Elixir Muse™, a privacy-first AI writing assistant that significantly minimizes the workload involved in drafting, editing, proofreading and translating text. Powered by Elixir Ai, the company's proprietary AI technology, Elixir Muse™ assists both writers and content creators improve the quality, clarity and consistency of their written content through advanced AI features - all while safeguarding the privacy of user data. Elixir Muse™ introduces a fundamentally different approach to AI-assisted document iteration: one where privacy and control are prioritized from the start, rather than being an afterthought. With user-friendly writing features and proven use cases, the product functions
Dubai Health and AGFA HealthCare Mark 20 Years of Collaboration Supporting Dubai's Healthcare System12.5.2026 11:30:00 CEST | Press release
Dubai Health and AGFA HealthCare have marked 20 years of collaboration supporting Dubai's healthcare system, reflecting a shared commitment to advancing integrated, patient-centered care. DUBAI, AE / ACCESS Newswire / May 12, 2026 / Over the past two decades, AGFA HealthCare has supported Dubai's healthcare system - most recently contributing to Dubai Health's integrated academic health system across care, learning, and research through a shared digital foundation. It enables clinicians access to critical information while maintaining data security, operational continuity, and patient confidentiality, and supports large-scale screening services in high-volume settings. The partnership has progressed from digitizing diagnostic imaging into a comprehensive enterprise imaging, analytics, and AI ecosystem that supports multiple clinical specialties, leadership decision-making, and population-scale healthcare services across Dubai Health's expanding network. Atif Al Braiki, Chief Digital an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom